Venture
from24/7 Wall St.
26 minutes agoFLY vs. Rocket Lab: Which Stock Has the Fuel to Break Orbit?
Increased interest in space exploration is driving investor focus on companies like SpaceX and others in the industry.
Freestone Grove, an equities-focused multimanager fund launched by Citadel alums, now has more than 180 employees, according to a March filing with regulators, while assets have eclipsed $6 billion and are poised to grow further as the firm opens up to select investors this year.
Eisen, an escheatment compliance platform that automates dormant account offboarding and unclaimed property reporting for regulated financial institutions, has raised $7.2M in funding according to a recent SEC filing.
President Trump issued a stark warning that without a deal by his Tuesday deadline, Iran would lose its power plants and bridges in a four-hour operation that sends the country back 'to the Stone Ages.'
The most attention-grabbing catalyst is the return of ticket sales. Virgin Galactic has resumed selling reservations for its upcoming commercial spaceflights, with seats now priced at $750,000 each. This marks a significant price increase from earlier reservation tiers and signals confidence that the company's Delta-class spacecraft will be ready to deliver on that premium.
The Vanguard S&P 500 Growth Index Fund ETF Shares tracks the S&P 500 Growth Index, which screens for companies with strong revenue growth, earnings growth, and price momentum. This results in a portfolio heavily weighted towards mega-cap technology and communication services, with Information Technology making up 41.4% of the fund.
Linx has built an AI-native platform that maps, monitors, and governs human, non-human, and agentic identities across the entire enterprise environment, relying on real-time detection and automated remediation to reduce identity-related risks.
Incyte tops this list due to its rare combination of commercial scale, cash generation, and pipeline depth. The company posted FY2025 revenue of $5.14 billion, up 21.2% YoY, anchored by Jakafi generating $828.2 million in Q4 2025 alone (+7% YoY) and Opzelura delivering $207.3 million (+28% YoY). With $3.58 billion in cash and 14 pivotal clinical trials underway, Incyte offers an acquirer immediate revenue, margin expansion potential, and a deep oncology pipeline spanning KRASG12D, CDK2 inhibition, and mutCALR.
Kato officially assumes her greatest challenge yet - CIO of Toyota's Woven Capital and CEO of Toyota Invention Partners. The latter appointment makes her the first female CEO of a wholly owned Toyota subsidiary.